Filtered By:
Vaccination: Varicella-Zoster Virus Vaccine
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 2051 results found since Jan 2013.
Prevention of Shingles in Dermatology Patients on Systemic Medications
Skin Therapy Lett. 2023 Jul;28(4):4-6.ABSTRACTThe lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, monotherapy with current biologics does not increase risk, however systemic steroids, Janus kinase inhibitors and combination biologic/conventional disease-modifying antirheumatics do. The recombinant zoster vaccine (RZV, Shingrix®), an adjuvanted non-live subunit vaccine against the glycoprotein E subunit of varicella zoster virus, is approve...
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Lyn Guenther Source Type: research
Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
Conclusion: Based on current evidence and a Delphi process, we provided consensus and updated recommendations on prophylaxis and treatment of infections to guide those caring for pediatric rheumatology patients. What is Known: •Data largely derived from adults find that infectious diseases and related complications are a major cause of morbidity and mortality in patients with immune-mediated rheumatic diseases. •It is crucial to be aware of the preventive measures that should be implemented to prevent these infections in children, although most guidelines are often extrapolated from adult cases. What is New: •In the ...
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Daniel Clemente Garulo Esmeralda N úñez-Cuadros Marisol Camacho Lovillo Joan Calzada-Hern ández Sara Guill én Martín Laura Fern ández Silveira Mar ía José Lirola Cruz Alfredo Tagarro Rosa Mar ía Alcobendas Rueda Agust ín López López Miren Satr Source Type: research
Prevention of Shingles in Dermatology Patients on Systemic Medications
Skin Therapy Lett. 2023 Jul;28(4):4-6.ABSTRACTThe lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, monotherapy with current biologics does not increase risk, however systemic steroids, Janus kinase inhibitors and combination biologic/conventional disease-modifying antirheumatics do. The recombinant zoster vaccine (RZV, Shingrix®), an adjuvanted non-live subunit vaccine against the glycoprotein E subunit of varicella zoster virus, is approve...
Source: Skin Therapy Letter - July 13, 2023 Category: Dermatology Authors: Lyn Guenther Source Type: research
Lower risk for COVID-19 hospitalization among patients in the United States with past vaccinations for herpes zoster and tetanus, diphtheria and pertussis
Prev Med Rep. 2023 Jun 25;35:102302. doi: 10.1016/j.pmedr.2023.102302. eCollection 2023 Oct.ABSTRACTInfluenza, tetanus, diphtheria, and herpes zoster (HZ) vaccination received within 10 years of the COVID-19 pandemic have been associated with less severe COVID-19 infection. We expanded on this evidence to determine if a receiving two different vaccinations (i.e., HZ and tetanus, diphtheria, and pertussis (Tdap)) was associated with a lower risk for COVID-19 hospitalization. De-identified medical record data from a large mid-western health care system was used to determine if, compared to those with neither HZ or Tdap vacci...
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Joanne Salas John E Morley Daniel F Hoft Jeffrey F Scherrer Source Type: research
Prevention of Shingles in Dermatology Patients on Systemic Medications
Skin Therapy Lett. 2023 Jul;28(4):4-6.ABSTRACTThe lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, monotherapy with current biologics does not increase risk, however systemic steroids, Janus kinase inhibitors and combination biologic/conventional disease-modifying antirheumatics do. The recombinant zoster vaccine (RZV, Shingrix®), an adjuvanted non-live subunit vaccine against the glycoprotein E subunit of varicella zoster virus, is approve...
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Lyn Guenther Source Type: research
Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis
Conclusion: Based on current evidence and a Delphi process, we provided consensus and updated recommendations on prophylaxis and treatment of infections to guide those caring for pediatric rheumatology patients. What is Known: •Data largely derived from adults find that infectious diseases and related complications are a major cause of morbidity and mortality in patients with immune-mediated rheumatic diseases. •It is crucial to be aware of the preventive measures that should be implemented to prevent these infections in children, although most guidelines are often extrapolated from adult cases. What is New: •In the ...
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Daniel Clemente Garulo Esmeralda N úñez-Cuadros Marisol Camacho Lovillo Joan Calzada-Hern ández Sara Guill én Martín Laura Fern ández Silveira Mar ía José Lirola Cruz Alfredo Tagarro Rosa Mar ía Alcobendas Rueda Agust ín López López Miren Satr Source Type: research
Prevention of Shingles in Dermatology Patients on Systemic Medications
Skin Therapy Lett. 2023 Jul;28(4):4-6.ABSTRACTThe lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, monotherapy with current biologics does not increase risk, however systemic steroids, Janus kinase inhibitors and combination biologic/conventional disease-modifying antirheumatics do. The recombinant zoster vaccine (RZV, Shingrix®), an adjuvanted non-live subunit vaccine against the glycoprotein E subunit of varicella zoster virus, is approve...
Source: Skin Therapy Letter - July 13, 2023 Category: Dermatology Authors: Lyn Guenther Source Type: research
